title: Effects of a common human gene variant of extracellular superoxide dismutase on endothelial function after endotoxin in mice.
abstract: A common gene variant in the heparin-binding domain (HBD) of extracellular superoxide dismutase (ECSOD) may predispose human carriers to ischaemic heart disease. We have demonstrated that the HBD of ECSOD is important for ECSOD to restore vascular dysfunction produced by endotoxin. The purpose of this study was to determine whether the gene variant in the HBD of ECSOD (ECSOD(R213G)) protects against endothelial dysfunction in a model of inflammation. We constructed a recombinant adenovirus that expresses ECSOD(R213G). Adenoviral vectors expressing ECSOD, ECSOD(R213G) or beta-galactosidase (LacZ, a control) were injected i.v. in mice. After 3 days, at which time the plasma SOD activity is maximal, vehicle or endotoxin (lipopolysaccharide or LPS, 40 mg kg(-1)) was injected i.p. Vasomotor function of aorta in vitro was examined 1 day later. Maximal relaxation to sodium nitroprusside was similar in aorta from normal and LPS-treated mice. Maximal relaxation to acetylcholine (10(-5)) was impaired after LPS and LacZ (63 +/- 3%, mean +/- s.e.m.) compared to normal vessels (83 +/- 3%) (P < 0.05). Gene transfer of ECSOD improved (P < 0.05) relaxation in response to acetylcholine (76 +/- 5%) after LPS, whereas gene transfer of ECSOD(R213G) had no effect (65 +/- 4%). Superoxide was increased in aorta (measured using lucigenin and hydroethidine) after LPS, and levels of superoxide were significantly reduced following ECSOD but not ECSOD(R213G). Thus, ECSOD reduces superoxide and improves relaxation to acetylcholine in the aorta after LPS, while the ECSOD variant R213G had minimal effect. These findings suggest that, in contrast to ECSOD, the common human gene variant of ECSOD fails to protect against endothelial dysfunction produced by an inflammatory stimulus.
authors: Department of Internal Medicine, Cardiovascular Center, University of Iowa Carver College of Medicine, Iowa City, Iowa 52242, USA.
authors: Donald D
authors: DD
authors: Lund
authors: Yi
authors: Y
authors: Chu
authors: Robert M
authors: RM
authors: Brooks
authors: Frank M
authors: FM
authors: Faraci
authors: Donald D
authors: DD
authors: Heistad
mesh_terms: D000109:Acetylcholine / Q000494:pharmacology; D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D001011:Aorta / Q000201:enzymology / Q000503:physiopathology; D015237:Dinoprost / Q000494:pharmacology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000187:drug effects / Q000201:enzymology / Q000503:physiopathology*; D017930:Genes, Reporter; D005822:Genetic Vectors; D006801:Humans; D007249:Inflammation / Q000201:enzymology / Q000503:physiopathology*; D007763:Lac Operon; D008070:Lipopolysaccharides; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009599:Nitroprusside / Q000494:pharmacology; D011110:Polymorphism, Genetic; D013482:Superoxide Dismutase / Q000235:genetics / Q000378:metabolism*; D013481:Superoxides / Q000378:metabolism; D014661:Vasoconstriction / Q000187:drug effects; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D014664:Vasodilation / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology; D001616:beta-Galactosidase
chemical_list: D008070:Lipopolysaccharides; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D013481:Superoxides; D009599:Nitroprusside; D015237:Dinoprost; C441642:SOD3 protein, human; D013482:Superoxide Dismutase; D001616:beta-Galactosidase; D000109:Acetylcholine
references: Am J Physiol Heart Circ Physiol. 2000 Oct;279(4):H1555-62
references: 11009441
references: Circ Res. 2000 Sep 29;87(7):E18-24
references: 11009571
references: Free Radic Biol Med. 2002 Mar 1;32(5):446-53
references: 11864784
references: Methods Enzymol. 2002;346:263-76
references: 11883072
references: Cardiovasc Res. 2002 Aug 1;55(2):239-49
references: 12123763
references: Circulation. 2002 Nov 5;106(19):2497-502
references: 12417549
references: Stroke. 2003 Feb;34(2):434-40
references: 12574556
references: Circ Res. 2003 Mar 7;92(4):461-8
references: 12600899
references: Shock. 2003 May;19(5):486-93
references: 12744495
references: Br J Pharmacol. 2003 May;139(2):444-56
references: 12770950
references: Circ Res. 2003 Oct 3;93(7):622-9
references: 12933702
references: Circulation. 2004 Jan 6;109(1):59-65
references: 14662715
references: Stroke. 2004 Aug;35(8):1963-7
references: 15218160
references: Am J Physiol Heart Circ Physiol. 2004 Aug;287(2):H805-11
references: 15277203
references: Mol Ther. 2004 Aug;10(2):344-54
references: 15294181
references: Clin Chim Acta. 1982 Nov 24;126(1):41-51
references: 7172448
references: Proc Natl Acad Sci U S A. 1982 Dec;79(24):7634-8
references: 6961438
references: Eur J Pharmacol. 1990 Nov 6;190(1-2):185-92
references: 1706272
references: Hum Mol Genet. 1994 Dec;3(12):2251-4
references: 7881430
references: Biochem J. 1996 Jan 1;313 ( Pt 1):235-9
references: 8546689
references: J Intern Med. 1997 Jul;242(1):5-14
references: 9260561
references: J Physiol Pharmacol. 1997 Dec;48(4):633-44
references: 9444612
references: Br J Pharmacol. 1998 Feb;123(3):525-37
references: 9504394
references: Circ Res. 1998 Jun 29;82(12):1298-305
references: 9648726
references: Am J Physiol. 1998 Aug;275(2 Pt 2):H416-21
references: 9683428
references: Stroke. 1999 Oct;30(10):2191-5; discussion 2195-6
references: 10512928
references: Am J Physiol Heart Circ Physiol. 2005 Aug;289(2):H624-30
references: 16014616
references: Mol Ther. 2005 Aug;12(2):321-7
references: 16043100
references: Circulation. 2005 Aug 16;112(7):1047-53
references: 16087794
references: Am J Physiol Heart Circ Physiol. 2006 Aug;291(2):H914-20
references: 16840738
references: Hypertension. 2000 Feb;35(2):595-601
references: 10679503
references: Nephron. 2000 Mar;84(3):218-23
references: 10720891
references: Pharmacol Res. 2001 Jul;44(1):22-7
references: 11428906